WO2023129956A2 - Dimethyltryptamine analogues as nitric oxide delivery drugs - Google Patents

Dimethyltryptamine analogues as nitric oxide delivery drugs Download PDF

Info

Publication number
WO2023129956A2
WO2023129956A2 PCT/US2022/082465 US2022082465W WO2023129956A2 WO 2023129956 A2 WO2023129956 A2 WO 2023129956A2 US 2022082465 W US2022082465 W US 2022082465W WO 2023129956 A2 WO2023129956 A2 WO 2023129956A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
alkyl
compound
ono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/082465
Other languages
English (en)
French (fr)
Other versions
WO2023129956A3 (en
Inventor
Robert B. Perni
Glenn Short
Tanweer Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Life Sciences AG
Original Assignee
Atai Life Sciences AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Life Sciences AG filed Critical Atai Life Sciences AG
Priority to JP2024539472A priority Critical patent/JP2024545787A/ja
Priority to AU2022425541A priority patent/AU2022425541A1/en
Priority to CA3238440A priority patent/CA3238440A1/en
Priority to EP22917527.8A priority patent/EP4457214A4/en
Publication of WO2023129956A2 publication Critical patent/WO2023129956A2/en
Publication of WO2023129956A3 publication Critical patent/WO2023129956A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present disclosure provides dimethyltryptamine derivatives that release nitric oxide (NO) in vivo.
  • NO nitric oxide
  • the present disclosure provides prodrugs of dimethyltryptamine and derivatives thereof.
  • the present disclosure provides compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts thereof.
  • R 7 and R 7 ’ are independently H, halogen, or C 1 -C 6 alkyl;
  • R2 is H or C 1 -C 6 alkyl
  • R 7 and R 7 ’ are independently H, halogen, or C 1 -C 6 alkyl
  • the present disclosure provides a pharmaceutical composition, comprising a compound of the present disclosure (e.g., compounds of Formula (I), (II) or Table 1) and a pharmaceutically acceptable excipient.
  • the present disclosure provides methods of using one or more compounds of the present disclosure (e.g., compounds of Formula (I), (II) or Table 1), e.g., as NO delivery agents.
  • compounds of Formula (I), (II) or Table 1 e.g., as NO delivery agents.
  • administer refers to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
  • treating refers to improving at least one symptom of the patient's or subject’s disorder.
  • treating can be improving, or at least partially ameliorating a disorder or one or more symptoms of a disorder.
  • terapéuticaally effective applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient or subject in need thereof.
  • salts includes both acid and base addition salts.
  • Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p- toluenesulfonate salts.
  • non-toxic acid addition salts i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p- toluene
  • Base addition salts include but are not limited to, ethylenediamine, N- methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.
  • lysine and arginine dicyclohexylamine and the like examples include metal salts include lithium, sodium, potassium, magnesium, calcium salts and the like.
  • metal salts include lithium, sodium, potassium, magnesium, calcium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
  • organic bases examples include lysine, arginine, guanidine, diethanolamine, choline and the like.
  • acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • C 1 -C 6 alkyl is intended to encompass Ci, C2, C3, C4, C5, Ce, Ci- 6, C1-5, Ci-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.
  • Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a C 1 -C 6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl.
  • a C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and Ci alkyl (z.e., methyl).
  • a C 1 -C 6 alkyl includes all moieties described above for C1-C5 alkyls but also includes Ce alkyls.
  • a C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C 1 -C 6 alkyls, but also includes C7, Cs, C9 and C10 alkyls.
  • a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls.
  • Non-limiting examples of C1-C12 alkyl include methyl, ethyl, zz-propyl, z-propyl, sec-propyl, zz-butyl, z-butyl, sec-butyl, t- butyl, w-pentyl, /-amyl, 77-hexyl, 77-heptyl, w-octyl, 77-nonyl, 77-decyl, w-undecyl, and w-dodecyl.
  • an alkyl group can be optionally substituted.
  • substituted means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclyl, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple-bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • R g and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, //-heterocyclyl, heterocyclylalkyl, heteroaryl, //-heteroaryl and/or heteroarylalkyl.
  • “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, /V-heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
  • the present disclosure provides dimethyltryptamine derivatives that release nitric oxide (NO) in vivo.
  • the present disclosure provides prodrugs of dimethyltryptamine and derivatives thereof.
  • the present disclosure provides compound of Formula (I) and (II), or pharmaceutically acceptable salts thereof.
  • R2 is independently C 1 -C 6 alkyl
  • R 1 isC 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 1 is methyl, ethyl, or propyl. In embodiments of the compounds of Formula (I), R 1 is methyl. In embodiments of the compounds of Formula (I), R 1 is H.
  • R 3 is H. In embodiments of the compounds of Formula (I), R 3 is halogen. In embodiments of the compounds of Formula (I), R 3 is C 1 -C 6 alkyl.
  • R 3 isH, halogen, or C 1 -C 6 alkyl.
  • R 3 is H or halogen.
  • R 3 isH or C 1 -C 6 alkyl.
  • R 3 is halogen orC 1 -C 6 alkyl.
  • R 4 is H, halogen, or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 4 is H or halogen. In embodiments of the compounds of Formula (I), R-i is H or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 4 is halogen or C 1 -C 6 alkyl.
  • R 5 is H. In embodiments of the compounds of Formula (I), R 5 is halogen. In embodiments of the compounds of Formula (I), R 5 is C 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 5 isH, halogen, or C 1 -C 6 alkyl.
  • R 5 is H or halogen. In embodiments of the compounds of Formula (I), R 5 isH or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 5 is halogen or C 1 -C 6 alkyl.
  • R 5 is -
  • R 7 and R 7 ’ are independently H or Ci- C 6 alkyl. In embodiments of the compounds of Formula (I), R 7 and R 7 ’ are independently H or Ci- C 3 alkyl. In embodiments of the compounds of Formula (I), R 7 and R 7 ’ are independently H or halogen alkyl. In embodiments of the compounds of Formula (I), R 7 and R 7 ’ are independently halogen or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (I), R 7 and R 7 ’ are independently halogen or C 1 -C 3 alkyl.
  • n is 1. In embodiments of the compounds of Formula (I), n is 2. In embodiments of the compounds of Formula (I), n is 3. In embodiments of the compounds of Formula (I), n is 4. In embodiments of the compounds of Formula (I), n is 5. [0040] In embodiments of the compounds of Formula (I), m is 2. In embodiments of the compounds of Formula (I), m is 3. In embodiments of the compounds of Formula (I), m is 4. In embodiments of the compounds of Formula (I), m is 5.
  • R 3 is H and X is absent. In embodiments of compounds of Formula (I), R 3 is halogen and X is absent. In embodiments of compounds of Formula (I), R 3 is H and X is O. In embodiments of compounds of Formula (I), R 3 is C 1 -C 6 alkyl and X is O. In embodiments of compounds of Formula (I), R 3 is Cl, F, Br, or I and X is absent. In embodiments of compounds of Formula (I), R 3 is F and X is absent.
  • R 4 is H and Y is absent. In embodiments of compounds of Formula (I), R 4 is halogen and Y is absent. In embodiments of compounds of Formula (I), R 4 is H and Y is O. In embodiments of compounds of Formula (II), R 4 is C 1 -C 6 alkyl and Y is O. In embodiments of compounds of Formula (I), R 4 is Cl, F, Br, or I and Y is absent. In embodiments of compounds of Formula (I), R 4 is F and Y is absent.
  • R 5 is H and Z is absent. In embodiments of compounds of Formula (I), R 5 is halogen and Z is absent. In embodiments of compounds of Formula (I), R 5 is H and Z is O. In embodiments of compounds of Formula (I), R 5 is C 1 -C 6 alkyl and Z is O. In embodiments of compounds of Formula (I), R 5 is Cl, F, Br, or I and Z is absent. In embodiments of compounds of Formula (II), R 5 is F and Z is absent.
  • R 2 is H or C 1 -C 6 alkyl; and R 7 and R 7 ’ are independently H, halogen, or C 1 -C 6 alkyl;
  • R 1 is C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 1 is methyl, ethyl, or propyl. In embodiments of the compounds of Formula (II), R 1 is methyl. In embodiments of the compounds of Formula (II), R 1 is H.
  • R 3 is H, halogen, or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is H or halogen. In embodiments of the compounds of Formula (II), R 3 isH or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is halogen or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is H. In embodiments of the compounds of Formula (II), R 3 is halogen. In embodiments of the compounds of Formula (II), R 3 is C 1 -C 6 alkyl.
  • R 4 is H, halogen, or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 4 is H or halogen. In embodiments of the compounds of Formula (II), FLi is H orC 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 4 is halogen or C 1 -C 6 alkyl.
  • R 3 is H, halogen, or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is H or halogen. In embodiments of the compounds of Formula (II), R 3 isH or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is halogen or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 3 is H. In embodiments of the compounds of Formula (II), R 3 is halogen. In embodiments of the compounds of Formula (II), R 3 is C 1 -C 6 alkyl.
  • Re is H or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), Re is C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), Re is methyl, ethyl, or propyl. In embodiments of the compounds of Formula (II), Re is methyl. In embodiments of the compounds of Formula (II), Re is H.
  • R 7 and R 7 ’ are independently H or Ci- Ce alkyl. In embodiments of the compounds of Formula (II), R? and R 7 ’ are independently H or C1-C3 alkyl. In embodiments of the compounds of Formula (II), R? and R 7 ’ are independently H or halogen alkyl. In embodiments of the compounds of Formula (II), R 7 and R 7 ’ are independently halogen or C 1 -C 6 alkyl. In embodiments of the compounds of Formula (II), R 7 and R 7 ’ are independently halogen or C1-C3 alkyl.
  • n is 1. In embodiments of the compounds of Formula (II), n is 2. In embodiments of the compounds of Formula (II), n is 3. In embodiments of the compounds of Formula (II), n is 4. In embodiments of the compounds of Formula (II), n is 5.
  • m is 2. In embodiments of the compounds of Formula (II), m is 3. In embodiments of the compounds of Formula (II), m is 4. In embodiments of the compounds of Formula (II), m is 5.
  • R 3 is H and X is absent. In embodiments of compounds of Formula (II), R 3 is halogen and X is absent. In embodiments of compounds of Formula (II), R 3 is H and X is O. In embodiments of compounds of Formula (II), R 3 is C 1 -C 6 alkyl and X is O. In embodiments of compounds of Formula (II), R 3 is Cl, F, Br, or I and X is absent. In embodiments of compounds of Formula (II), R 3 is F and X is absent. [0066] In embodiments of the compounds of Formula (II), R 4 is H and Y is absent.
  • R 4 is halogen and Y is absent. In embodiments of compounds of Formula (II), R 4 is H and Y is O. In embodiments of compounds of Formula (II), R 4 is C 1 -C 6 alkyl and Y is O. In embodiments of compounds of Formula (II), R 4 is Cl, F, Br, or I and Y is absent. In embodiments of compounds of Formula (II), R 4 is F and Y is absent.
  • R 3 is H and Z is absent. In embodiments of compounds of Formula (II), R 3 is halogen and Z is absent. In embodiments of compounds of Formula (II), R 3 is H and Z is O. In embodiments of compounds of Formula (II), R 3 is C 1 -C 6 alkyl and Z is O. In embodiments of compounds of Formula (II), R 5 is C1, F, Br, or I and Z is absent. In embodiments of compounds of Formula (II), R 3 is F and Z is absent.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of the present disclosure (e.g., a compound of Formula (I), (II), or Table 1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent.
  • suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions.
  • suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.
  • the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques.
  • Intraarterial and intravenous injection as used herein includes administration through catheters.
  • the present disclosure provides methods of treating a disease or disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound described herein (e.g., a compound of Formula (I), (II), or Table 1) or pharmaceutically acceptable salt thereof to the subject.
  • a compound described herein e.g., a compound of Formula (I), (II), or Table 1
  • pharmaceutically acceptable salt thereof e.g., a compound described herein (e.g., a compound of Formula (I), (II), or Table 1) or pharmaceutically acceptable salt thereof to the subject.
  • the disease or disorder is a mental health disease or disorder.
  • the mental health disease or disorder is selected from the group consisting of major depressive disorder, treatment resistant depression, substance use disorders and eating disorders.
  • eating disorders include illnesses such as anorexia nervosa, bulimia nervosa, and other disorders related to eating (e.g., binge eating).
  • the mental health disease or disorder is an eating disorder.
  • the mental health disease or disorder is selected from the group consisting of compulsive disorders, anxiety disorders, stress disorders, and rumination.
  • the mental health disease or disorder is a mood disorder.
  • mood disorders include e.g., depressive disorders, such as major depressive disorder or treatment resistant depression.
  • the mental health disorder is a substance abuse disorder.
  • substance use related disorders are disorders of maladaptive patterns of substance use, and include criteria, such as recurrent substance use related problems, tolerance to a substance, withdrawal upon discontinuing use, an inability to cut down or control use of the substance, and giving up important social, occupational, or recreational activities because of using the substance. See e.g., the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
  • the substance use related disorder is a disorder resulting from the use of: alcohol; caffeine; cannabis; hallucinogens (such as phencyclidine or similarly acting arylcyclohexylamines, and other hallucinogens, such as LSD); inhalants; opioids; sedatives, hypnotics, or anxiolytics; stimulants (including amphetamine-type substances, cocaine, and other stimulants); tobacco; and other substances.
  • hallucinogens such as phencyclidine or similarly acting arylcyclohexylamines, and other hallucinogens, such as LSD
  • inhalants opioids
  • stimulants including amphetamine-type substances, cocaine, and other stimulants
  • tobacco and other substances.
  • administering compounds of the present disclosure e.g., a compound of Formula (I), (II), or Table 1) or a pharmaceutically acceptable salt thereof releases nitric oxide (NO) (e.g., the compounds of the present disclosure are NO delivery drugs).
  • NO nitric oxide
  • the compounds of the present disclosure are useful for releasing NO in vivo.
  • R 2 is H or C 1 -C 6 alkyl; and R 7 and R 7 ’ are independently H, halogen, or C 1 -C 6 alkyl;
  • a pharmaceutical composition comprising a compound of any one of embodiments 1-28 and a pharmaceutically acceptable excipient.
  • a method of treating a mental health disease or disorder comprising administering a therapeutically effective amount of a compound of any one of embodiments 1-28 or pharmaceutical composition of embodiment 29.
  • R 2 is C 1 -C 6 alkyl
  • a pharmaceutical composition comprising a compound of any one of embodiments 31- 50 and a pharmaceutically acceptable excipient.
  • a method of treating a mental health disease or disorder comprising administering a therapeutically effective amount of a compound of any one of embodiments 31- 50 or pharmaceutical composition of embodiment 51.
  • Example 1 Methods of preparing the compounds of the present disclosure
  • Prodrug 2-1 was synthesized from commercially available intermediate 2-1-1 and 2-1-3 in three steps and described in the Scheme 1. [0079]
  • Desired product could be detected by LCMS.
  • the resulting mixture was filtered, the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 : 1) to afford intermediate as a yellow solid.
  • Desired product could be detected by LCMS.
  • the reaction was quenched with MeOH at 0°C.
  • the resulting mixture was concentrated under vacuum.
  • the residue was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water (0.1% FA), 5% to 80% gradient in 40 min; detector, UV 254 nm. to afford 25 mg of l-(3-(2-(dimethylamino)ethyl)-lH-indol-l-yl)-4-(nitrooxy)butanoate (2-1) as a white solid.
  • LCMS of 2-1 [M+H] + 320.10

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2022/082465 2021-12-30 2022-12-28 Dimethyltryptamine analogues as nitric oxide delivery drugs Ceased WO2023129956A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2024539472A JP2024545787A (ja) 2021-12-30 2022-12-28 一酸化窒素送達剤としてのジメチルトリプタミン類似体
AU2022425541A AU2022425541A1 (en) 2021-12-30 2022-12-28 Dimethyltryptamine analogues as nitric oxide delivery drugs
CA3238440A CA3238440A1 (en) 2021-12-30 2022-12-28 Dimethyltryptamine analogues as nitric oxide delivery drugs
EP22917527.8A EP4457214A4 (en) 2021-12-30 2022-12-28 DIMETHYLTRYPTAMINE ANALOGUES USED AS NITRIC OXIDE ADMINISTRATION MEDICINES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163295199P 2021-12-30 2021-12-30
US63/295,199 2021-12-30

Publications (2)

Publication Number Publication Date
WO2023129956A2 true WO2023129956A2 (en) 2023-07-06
WO2023129956A3 WO2023129956A3 (en) 2023-08-31

Family

ID=87000269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082465 Ceased WO2023129956A2 (en) 2021-12-30 2022-12-28 Dimethyltryptamine analogues as nitric oxide delivery drugs

Country Status (6)

Country Link
US (2) US12012381B2 (https=)
EP (1) EP4457214A4 (https=)
JP (1) JP2024545787A (https=)
AU (1) AU2022425541A1 (https=)
CA (1) CA3238440A1 (https=)
WO (1) WO2023129956A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065405B2 (en) 2021-06-09 2024-08-20 Atai Therapeutics, Inc. Prodrugs and conjugates of dimethyltryptamine
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12606525B2 (en) 2021-12-30 2026-04-21 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4584247A2 (en) * 2022-09-06 2025-07-16 ATAI Therapeutics, Inc. Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US860913A (en) 1906-09-13 1907-07-23 Max Haeberlein Oil-brake for speed-governors.
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
US3594391A (en) 1969-06-09 1971-07-20 American Home Prod 2-halo-3-substituted indoles
US3781300A (en) 1969-06-09 1973-12-25 American Home Prod Method of producing 2-halo-3-substituted indoles
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2102303A1 (en) 1991-06-19 1992-12-20 Roy Allen Johnson Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
JP3361836B2 (ja) * 1991-07-04 2003-01-07 三共株式会社 アミノ酸誘導体
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
DE69411143T2 (de) 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
AU679635B2 (en) 1994-03-11 1997-07-03 Eli Lilly And Company Method for treating 5HT-2B receptor related conditions
US6025374A (en) 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6500456B1 (en) 1997-10-03 2002-12-31 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20050245594A1 (en) 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
WO2003026559A2 (en) 2001-09-28 2003-04-03 Kurve Technology, Inc Nasal nebulizer
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
CA2562783A1 (en) * 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2006099416A1 (en) * 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
RU2406480C2 (ru) 2005-04-08 2010-12-20 Озфарма Пти Лтд Трансбуккальная система доставки
CA2633588A1 (en) 2005-12-20 2007-08-23 Teikoku Pharma Usa, Inc. Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
CN101395164A (zh) 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
EP1993541A2 (en) 2006-02-17 2008-11-26 Gilead Colorado, Inc. Antihypertensive therapy
WO2008003028A2 (en) 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US20080318957A1 (en) 2007-05-11 2008-12-25 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
EP2435043A1 (en) 2009-05-27 2012-04-04 Université Libre de Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
EP2464227A4 (en) 2009-08-10 2013-02-20 Galenea Corp COMPOUNDS AND METHODS OF USE
WO2011041870A1 (en) * 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
EP2771341A4 (en) 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2014134127A1 (en) * 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
EP2796139A1 (en) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
US9549942B2 (en) 2013-07-15 2017-01-24 Research & Business Foundation Sungkyunkwan University Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins
CA2931345A1 (en) 2013-11-24 2015-05-28 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
US9732103B2 (en) 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
US11078467B2 (en) 2016-10-26 2021-08-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CN110177581B (zh) 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
US11261157B2 (en) 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
BR112020004116A2 (pt) 2017-08-28 2020-09-01 University Of Maryland, Baltimore novos moduladores do receptor de ácido gama aminobutírico tipo a para distúrbios de humor
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
MX2020009254A (es) 2018-03-08 2021-01-15 New Atlas Biotechnologies Llc Procesos para la produccion de triptaminas.
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
AU2019324952B2 (en) 2018-08-22 2024-10-24 University Of Technology Sydney NBOMe test
WO2020096587A1 (en) 2018-11-07 2020-05-14 Baxter International Inc. Dual check valve one handed applicator
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
HUE069534T2 (hu) 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
CA3132731A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
EP4017859A4 (en) * 2019-08-25 2023-08-23 Caamtech, LLC ALKYL QUARTERNARY AMMONIUM TRYPTAMINE AND THEIR THERAPEUTIC USES
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
CA3166785A1 (en) 2020-02-05 2021-08-12 Yale University Psychedelic treatment for headache disorders
KR20260008838A (ko) 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
US11753375B2 (en) 2020-03-19 2023-09-12 Caamtech, Inc. Crystalline psilacetin derivatives
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US11358934B2 (en) 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin
MX2022012537A (es) 2020-04-16 2022-11-07 Pike Therapeutics Inc Entrega transdermica de microdosis de derivados psicodelicos.
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
WO2021226041A1 (en) 2020-05-04 2021-11-11 Caamtech, Inc. Crystalline dimethyl tryptamine analogues
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
EP4167992A1 (en) 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
CN119285527A (zh) 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
IL301066A (en) 2020-09-04 2023-05-01 Gilgamesh Pharmaceuticals Inc Azetidinyl tryptamines and methods for the treatment of psychiatric disorders
AU2021343525A1 (en) 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022082058A1 (en) 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
WO2022109050A1 (en) 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
WO2022123232A1 (en) 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
AU2022206448B2 (en) 2021-01-11 2024-04-18 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses
WO2022160056A1 (en) 2021-01-29 2022-08-04 Algernon Pharmaceuticals Inc. Dmt salts and their use to treat brain injury
US20240189331A1 (en) 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
WO2022195011A1 (en) 2021-03-18 2022-09-22 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use
JP2024517738A (ja) 2021-04-26 2024-04-23 アタイ セラピューティクス， インコーポレイテッド 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
JP2024517194A (ja) 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
KR20240009433A (ko) 2021-05-17 2024-01-22 사이빈 아이알엘 리미티드 실로시빈의 제형
CA3218110A1 (en) 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
BR112023024688A2 (pt) 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
EP4366729A4 (en) 2021-07-07 2025-06-11 Arcadia Medicine, Inc. SAFER PSYCHOACTIVE COMPOSITIONS
EP4137131A1 (en) 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
JP2024533291A (ja) 2021-09-08 2024-09-12 サイビン アイアールエル リミテッド 併用薬物療法
US20230099972A1 (en) 2021-09-30 2023-03-30 ATAI Life Sciences AG Compositions and methods for treating headaches
US20230310374A1 (en) 2021-09-30 2023-10-05 ATAI Life Sciences AG Compositions and methods for treating headache or facial pain
WO2023076150A1 (en) 2021-10-29 2023-05-04 Psilera Inc. Modified indole compounds
WO2023076135A1 (en) 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
EP4448488A2 (en) 2021-12-13 2024-10-23 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
WO2023115167A1 (en) 2021-12-24 2023-06-29 Psylo Pty Ltd Compounds
CN118974044A (zh) 2021-12-24 2024-11-15 赛洛私人有限公司 化合物
US11912680B2 (en) * 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4584247A2 (en) 2022-09-06 2025-07-16 ATAI Therapeutics, Inc. Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
CA3267555A1 (en) 2022-10-26 2024-05-02 Atai Therapeutics, Inc. Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use
WO2024118767A2 (en) 2022-11-29 2024-06-06 Caamtech, Inc. Tryptamine derivatives
TW202430149A (zh) 2022-12-01 2024-08-01 美商雅特益醫療公司 Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法
WO2024130140A2 (en) 2022-12-15 2024-06-20 Atai Therapeutics, Inc. Prodrugs of dimethyltryptamine and derivatives thereof
EP4704833A2 (en) 2023-04-27 2026-03-11 ATAI Therapeutics, Inc. Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
KR20260013222A (ko) 2023-05-24 2026-01-27 실로라 인코퍼레이티드 트립타민 유도체를 함유하는 제제 및 그의 용도
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025019800A1 (en) 2023-07-19 2025-01-23 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
WO2025024637A1 (en) 2023-07-25 2025-01-30 Atai Therapeutics, Inc. Compositions for limiting sympathomimetic effects of psychedelic therapeutics
WO2025054397A1 (en) 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
WO2025137581A1 (en) 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions
WO2025170990A1 (en) 2024-02-06 2025-08-14 Atai Therapeutics, Inc. Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396982B2 (en) 2020-05-08 2025-08-26 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12472163B2 (en) 2020-05-08 2025-11-18 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
US12065405B2 (en) 2021-06-09 2024-08-20 Atai Therapeutics, Inc. Prodrugs and conjugates of dimethyltryptamine
US12606525B2 (en) 2021-12-30 2026-04-21 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs

Also Published As

Publication number Publication date
US12012381B2 (en) 2024-06-18
US20240400511A1 (en) 2024-12-05
US12606525B2 (en) 2026-04-21
WO2023129956A3 (en) 2023-08-31
CA3238440A1 (en) 2023-07-06
EP4457214A2 (en) 2024-11-06
AU2022425541A1 (en) 2024-06-06
EP4457214A4 (en) 2025-12-03
JP2024545787A (ja) 2024-12-11
US20230227407A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
WO2023129956A2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
AU2021224733A1 (en) Pyridopyrimidine derivatives as KRAS inhibitors
WO2023129958A2 (en) Nitric oxide releasing prodrugs of mda and mdma
JP5244179B2 (ja) （（１ｓ）−１−（（（２ｓ）−２−（５−（４’−（２−（（２ｓ）−１−（（２ｓ）−２−（（メトキシカルボニル）アミノ）−３−メチルブタノイル）−２−ピロリジニル）−１ｈ−イミダゾール−５−イル）−４−ビフェニリル）−１ｈ−イミダゾール−２−イル）−１−ピロリジニル）カルボニル）−２−メチルプロピル）カルバミン酸メチル二塩酸塩の結晶形
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
JP2016506959A5 (https=)
JP2025530932A (ja) カンプトテシン－７－エチルアミン誘導体、及びその調製方法、並びに使用
ES2942034T3 (es) Procedimiento para preparar n-((1r,2s,5s)-2-((2-((5-cloropiridin-2-il)amino)-2-oxoacetil)amino)-5-(dimetilcarbamoil) ciclohexil)carbamato de terc-butilo
TR201909016T4 (tr) (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri.
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JPWO2020138481A1 (ja) ピロリジン化合物の結晶
JP2022537140A5 (https=)
JP2023548342A5 (https=)
WO2015093586A1 (ja) トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
JP6516758B2 (ja) 抗菌ペプチド模倣物
RU2007125658A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
JP2022544057A5 (https=)
JP2025513454A5 (https=)
EP2235022B1 (en) Dimeric derivatives of artemisinin and application in anticancer therapy
TW200530255A (en) 3-pyridiniummethylcefem compound
WO2013050426A1 (en) Carbonic anhydrase inhibitor comprising a dithiocarbamate
WO2021062168A1 (en) Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
JP2011529907A (ja) イソホスホルアミドマスタードおよびその類似体の合成および製剤
AU2014343754B2 (en) Metallocene derivatives with anticancer activity
JP2024528253A (ja) Ｎａｖ １．７及び／又はｎａｖ １．８を阻害することができるｎ－アシルヒドラゾン化合物、その調製方法、それを使用して治療するための組成物、使用、方法並びにキット

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22917527

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3238440

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2022425541

Country of ref document: AU

Ref document number: AU2022425541

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2022425541

Country of ref document: AU

Date of ref document: 20221228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024539472

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022917527

Country of ref document: EP

Effective date: 20240730